Oliver Pfaar Ioana Agache Frédéric de Blay Sergio Bonini Adam M. Chaker Stephen R. Durham Radoslaw Gawlik Peter W. Hellings Marek Jutel Jörg Kleine‐Tebbe Ludger Klimek Matthias V. Kopp Andreas Nandy Ronald L. Rabin Ronald van Ree Harald Renz Graham Roberts Anne‐Marie Salapatek Carsten B. Schmidt‐Weber Mohamed H. Shamji Gunter J. Sturm J. Christian Virchow Ulrich Wahn Christoph Willers Petra Zieglmayer Cezmi A. Akdis
Abstract
Abstract
The seventh “Future of the Allergists and Specific Immunotherapy (FASIT)” workshop held in 2019 provided a platform for global experts from academia, allergy clinics, regulatory authorities and industry to review current developments in the field of allergen immunotherapy (AIT). Key domains of the meeting included the following: (a) Biomarkers for AIT and allergic asthma; (b) visions for the future of AIT; (c) progress and data for AIT in asthma and the updates of GINA and EAACI Asthma Guidelines (separated for house dust mite SCIT, SLIT tablets and SLIT drops; patient populations) including a review of clinically relevant endpoints in AIT studies in asthma; (d) regulatory prerequisites such as the “Therapy Allergen Ordinance” in Germany; (e) optimization of trial design in AIT clinical research; (f) challenges planning and conducting phase III (field) studies and the future role of Allergen Exposure Chambers (AEC) in AIT product development from the regulatory point of view. We report a summary of panel discussions of all six domains and highlight unmet needs and possible solutions for the future.
PDF
No comments:
Post a Comment